KRAS and cancer: As shown in Fig. 4c, d, TCRA3V and TCRA11V-expressing CD8+ T cells exhibited specific cytotoxicity, irrespective of tissue of origin, against all HLA-A*03:01 or HLA-A*11:01-matched KRAS G12V+ cancer cell lines, respectively.